CMDX Establishes Facility in the MaRS Discovery District in Toronto
News Apr 11, 2006
Acacia Research Corporation has announced that its CombiMatrix group’s wholly-owned subsidiary CombiMatrix Molecular Diagnostics (CMDX) has established a new facility in the MaRS Discovery District in downtown Toronto.
"With the abundance of stellar scientists and research and clinical activities in and around the MaRS discovery district and the fact that our Chief Scientific Officer and Vice President, Dr. Mansoor Mohammed, is a Canadian citizen, it was an easy and obvious choice for our expansion into the Canadian arena," said Dr. Amit Kumar, CEO of CombiMatrix.
"Moving forward we anticipate establishing strong relationships with Canadian customers, partners and the government."
"Ontario’s highly-skilled workforce, leading-edge research and proven ability to discover new ideas and turn them into innovative products is helping build a pervasive culture of innovation in our province," said Premier and Minister of Research and Innovation, Dalton McGuinty.
"The MaRS Discovery District supports the discovery, funding and marketing of new ideas all in the same building. With its strong reputation for leading-edge research, CMDX is a welcome addition to this world-class facility."
"We are delighted to welcome Dr. Mohammed and CMDX to the MaRS Discovery District," said Dr. Ilse Treurnicht, MaRS CEO.
"MaRS is dedicated to building a global gateway to Ontario research and innovation, and attracting world-class companies like CMDX is a critical component of our strategy."
"Toronto’s vibrant medical and research institutions have long since demonstrated a strong track record for clinical trials initiatives with several of the world’s leading pharmaceutical entities," added Dr. Mohammed, Chief Scientific Officer and Vice President of CMDX.
"By placing our transformative genomic microarray technologies at the very epicenter of these activities, we anticipate creating a one-of-a-kind fusion between pharmacogenomic pursuits and genomics-based diagnostics."
"I am very excited to be involved in this expansion of CNIDX and I am particularly proud to see its manifestation in Toronto."
"We anticipate drawing heavily from the exceptionally well-qualified researchers trained within the greater Tomato medical renewal community and I am eager to see to fruition the commercialization of novel, high value gene- based diagnostic products and services that I sin certain will follow from oar Canadian activities."
Scientists used a gene editing method called CRISPR/Cas9 to generate mice that faithfully mimic a fatal respiratory disorder in newborn infants that turns their lips and skin blue. The new laboratory model allowed researchers to pinpoint the ailment's cause and develop a potential and desperately needed nanoparticle-based treatment.READ MORE